Valneva SE Company Investigated by the Portnoy Law Firm

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Valneva SE, particularly following adverse events related to its chikungunya virus vaccine, IXCHIQ, which may lead to a class action lawsuit for affected investors [1][3]. Group 1: Investigation and Legal Actions - The Portnoy Law Firm is advising Valneva investors who have incurred losses to contact them for potential legal recourse [1][2]. - The firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [5]. Group 2: Impact of CDC Announcement - On February 25, 2025, the CDC announced an investigation into five cases of hospitalization involving cardiac or neurological events in individuals aged 65 and older who received IXCHIQ [3]. - Following the CDC's announcement, Valneva's American Depositary Receipts (ADRs) fell by $1.06, or approximately 13.57%, closing at $6.75 per ADR on February 28, 2025 [4].